Patient characteristics of measurable lesion type in talimogene laherparepvec study

Any Measurable LesionEvaluablea LesionEvaluable for overall lesion- type burdenb
n (%)n (%)n (%)
Any50 (100)47 (100)37 (100)
At least 1 baseline uninjected lesion48 (96.0)41 (87.2)35 (94.6)
Baseline uninjected, non-visceral only26 (52.0)23 (48.9)23 (62.2)
At least 1 visceral lesion at baseline22 (44.0)15 (31.9)12 (32.4)

Denominators are the numbers of patients

aEvaluable indicates at least 2 assessments with valid measurements per investigator

bEvaluable indicates at least 2 visits with non-missing overall lesion-type burden for each respective patient subgroup, or overall tumor burden for “Any”

All patients received at least one dose of talimogene laherparepvec